The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Low volume on the Naz, Lago have no shares to offload! If they don't start buying from AIM im expecting a drop in SP.
Hold onto them golden tickets as 'Significant shareholder value' is now within the 3 - 7 Month range!!!!
LAGO sold their shares on the naz already. Expecting more 5k traders this afternoon
Maybe there is something in that detail that we are missing , i.e that is worth or needs to be RNS'd .
Either way , its nice that the MATINS trial is both ongoing to schedule and still being seen as promising by investigators .
And SP is holding well and rising slightly .
No matter that it don't help, the share price is showing positive momentum. Objectives achieved with our 'meaningless' RNS that reinforces progress with life saving initiatives.
We need Zengah to navigate the road ahead to £25 :0))
Nice to see LAGO back..................
Very true this doesn’t help really
i dont like it when RNS dont start with the phrase "is pleased to announce" lol
I am a bit confused as to the reason for that rns. Not sure what the purpose was, given no new data???
Typical Faron update...very positive but so down played...if this was another company this would be fanfared.
Still think bigger things are happening in the background so great times ahead.
Am I right in saying that there is nothing in this we didn’t already know?
‘The presentation includes previously announced data, highlighting:‘
These data are from patients with difficult-to-treat cancers who had already failed all standard therapy options and received as many as six different lines of therapy, exhausting all future treatment options.
'It Works!'
TURKU - FINLAND, 18 September 2020 - Faron Pharmaceuticals Ltd ("Faron") (LON: FARN), the clinical stage biopharmaceutical company, today announces details from an oral presentation being held at the European Society of Medical Oncology (ESMO) Virtual Congress 2020, showcasing data from the Company's ongoing MATINS trial to the scientific community.
The ongoing phase I/II MATINS clinical trial is investigating the tolerability, safety and efficacy of bexmarilimab, Faron's wholly-owned novel precision cancer immunotherapy targeting Clever-1 positive tumour associated macrophages (TAM) in selected metastatic or inoperable solid tumours. During the on-demand mini oral session, Petri Bono, M.D., Ph.D., principal investigator of the MATINS study, presents data on all 30 patients in Part I of the trial with advanced solid tumours and who had exhausted standard therapeutic options. The presentation includes previously announced data, highlighting:
· Key pharmacokinetics (PK) and Clever-1 receptor occupancy data showing that exposure to bexmarilimab in the trial was more than dose proportional, that full (transient) Clever-1 receptor occupancy was achieved and, despite its relatively fast clearance from circulation, sustained pharmacodynamic effects by bexmarilimab were observed.
· Very good tolerability across all dosing levels with no observed dose limiting toxicity.
· Th1-weighted immune activation in all subjects measured following treatment with bexmarilimab. The patients also increased circulating CD8+ T cells and CD8+/CD4+ ratio, decreased regulatory T-cells (T-regs) or had a substantial increase in natural killer cells in the blood, all of which are considered as strong signs of this desired immune activation.
· Promising clinical anti-tumour activity including, 1) a long-lasting partial response of a heavily pre-treated microsatellite stable metastatic colorectal cancer patient who had previously been treated with six different anti-cancer drugs, which had all failed, 2) target lesion responses in heavily pre-treated melanoma and ovarian cancer patients.
· Conversion of immunologically non-inflamed (cold) tumours into inflamed (hot) tumours in patients traditionally not responsive to currently available checkpoint inhibitors.
Commenting on the presented data, Petri Bono M.D., Ph.D., Terveystalo, Helsinki, Finland and principal investigator of the MATINS trial, said: "The emerging tolerability profile and evidence of clinical anti-tumour activity for this novel anti Clever-1 antibody are promising. These data are from patients with difficult-to-treat cancers who had already failed all standard therapy options and received as many as six different lines of therapy, exhausting all future treatment options. As this trial continues, we will learn more about this novel immunotherapy's potential to help those cancer patients who desperately need new treatment options."
Title: A phase I/II MATINS trial: Part 1 pharmacokinetic, safety an